Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Ministry for Health and Solidarity, France | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Multi-institutional registry on a cohort of 310 patients with biopsy-proven renal cell carcinoma treated by Radiofrequency ablation. All patients will be included consecutively and retrospectively in all centers to obtain the required number of patient followed during 5 years.
Radiofrequency ablation (RFA) of renal cell carcinoma (RCC) is actually used in elderly patients with small renal tumors (diameter ≤ 4 cm) and presenting a high risk of surgery (due to co-morbidity) and/or reduced renal function. RFA is a minimally invasive technique, considered as an alternative to surgery to limit morbidity and to preserve kidney function. The technique is well known and has proven his efficacy for the treatment of small tumors.
An enlargement of the indications of RFA to patient without contra-indication to surgery will depend on the efficacy of the technique.
The main objective of the study is to evaluate the local efficacy of the ablation based on the technical success, and on the evaluation of local cancer recurrence over 5 years.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| patients | Treated by percutaneous image-guided radiofrequency for renal tumor |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Rate of local efficacy of RFA treatment | 60 months after the RFA treatment (D0) |
| Measure | Description | Time Frame |
|---|---|---|
| Overall success | At 60 months after the RFA treatment (D0) | |
| No recurrence of RCC | At 60 months after the RFA treatment (D0) | |
| Tolerance of the treatment |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
The population concerned by the study consists in patients treated by percutaneous image-guided radiofrequency for renal tumor. The treated tumors have a diameter ≤ 4 cm characterized by computed tomography (CT) or Magnetic resonance imaging (MRI).
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Paul PEREZ, MD | University Hospital Bordeaux, France | Study Chair |
| Nicolas GRENIER, Prof | University Hospital Bordeaux, France | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| CHU de Bordeaux - Pellegrin | Bordeaux | France | ||||
| CHU de Grenoble |
Not provided
| ID | Term |
|---|---|
| D002292 | Carcinoma, Renal Cell |
| ID | Term |
|---|---|
| D000230 | Adenocarcinoma |
| D002277 | Carcinoma |
| D009375 | Neoplasms, Glandular and Epithelial |
| D009370 | Neoplasms by Histologic Type |
Not provided
Not provided
Not provided
Not provided
Not provided
| At D0, 48 hours, 6, 12, 24, 36, 48 and 60 months after the RFA treatment (D0) |
| Grenoble |
| France |
| CHRU de Lille - Hôpital Claude HURIEZ | Lille | France |
| Hospices Civils de Lyon | Lyon | France |
| Assistance Publique - Hôpitaux de Marseille | Marseille | France |
| Assistance Publique - Hôpitaux de Paris (AP-HP) - Hopital Necker | Paris | France |
| CHU de Strasbourg | Strasbourg | France |
| CHU de Toulouse, Hopital de Rangueil | Toulouse | France |
| D009369 | Neoplasms |
| D007680 | Kidney Neoplasms |
| D014571 | Urologic Neoplasms |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D007674 | Kidney Diseases |
| D014570 | Urologic Diseases |
| D052801 | Male Urogenital Diseases |